Aeon Biopharma Inc (AEON)

$1.34

-0.21

(-13.55%)

Market is closed - opens 7 PM, 20 Jun 2024

Insights on Aeon Biopharma Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.6% return, outperforming this stock by 160.2%

Performance

  • $1.34
    $1.55
    $1.34
    downward going graph

    0.0%

    Downside

    Day's Volatility :13.54%

    Upside

    13.54%

    downward going graph
  • $1.26
    $17.17
    $1.34
    downward going graph

    5.97%

    Downside

    52 Weeks Volatility :92.66%

    Upside

    92.2%

    downward going graph

Returns

PeriodAeon Biopharma IncIndex (Russel 2000)
3 Months
-90.69%
0.0%
6 Months
-77.29%
0.0%
1 Year
-84.48%
0.0%
3 Years
-86.11%
-20.9%

Highlights

Market Capitalization
54.4M
Book Value
- $5.2
Earnings Per Share (EPS)
-0.29
Wall Street Target Price
6.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-374.77%
Return On Equity TTM
0.0%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-50.1M
Diluted Eps TTM
-0.29
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.8
EPS Estimate Next Year
-0.87
EPS Estimate Current Quarter
-0.31
EPS Estimate Next Quarter
-0.31

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Aeon Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 347.76%

Current $1.34
Target $6.00

Technicals Summary

Sell

Neutral

Buy

Aeon Biopharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aeon Biopharma Inc
Aeon Biopharma Inc
-21.18%
-77.29%
-84.48%
-86.11%
-86.11%
Moderna, Inc.
Moderna, Inc.
-5.49%
49.59%
7.28%
-36.0%
759.81%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.25%
22.48%
33.01%
94.49%
234.3%
Novo Nordisk A/s
Novo Nordisk A/s
5.94%
40.81%
74.18%
240.71%
437.2%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.8%
15.91%
36.36%
148.95%
157.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aeon Biopharma Inc
Aeon Biopharma Inc
NA
NA
NA
-3.8
0.0
-3.75
NA
-5.2
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.72
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.58
30.58
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.48
49.48
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.16
31.16
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aeon Biopharma Inc
Aeon Biopharma Inc
Buy
$54.4M
-86.11%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$53.7B
759.81%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.2B
234.3%
30.58
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$636.1B
437.2%
49.48
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.1B
157.1%
31.16
39.46%

Company Information

we are a nasdaq-listed special purpose acquisition company whose business purpose is to effect a merger or similar business combination with one or more businesses. our acquisition strategy is to identify and complete our initial business combination with a medical technology company in the healthcare industry. our sponsor team consists of chairman/ceo robert palmisano, president vikram malik, cfo oleg grodnensky and chief legal officer david meredith.

Organization
Aeon Biopharma Inc
Employees
10
CEO
Mr. Marc Forth
Industry
Miscellaneous

FAQs